Efficacy of Afatinib and Lapatinib Against HER2 Gene-amplified Trastuzumab-sensitive and -resistant Human Gastric Cancer Cells

SUSUMU NAKATA; MITSUGU FUJITA; HAYAO NAKANISHI

doi:10.21873/anticanres.13797

Research ArticleExperimental Studies

Efficacy of Afatinib and Lapatinib Against HER2 Gene-amplified Trastuzumab-sensitive and -resistant Human Gastric Cancer Cells

SUSUMU NAKATA, MITSUGU FUJITA and HAYAO NAKANISHI

Anticancer Research November 2019, 39 (11) 5927-5932; DOI: https://doi.org/10.21873/anticanres.13797

SUSUMU NAKATA

1Department of Clinical Oncology, Kyoto Pharmaceutical University, Kyoto, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: snakata@mb.kyoto-phu.ac.jp

MITSUGU FUJITA

2Department of Microbiology, Faculty of Medicine, Kindai University, Osaka, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

HAYAO NAKANISHI

3Department of Gastroenterological Surgery, Graduate School of Medicine, Nagoya University, Nagoya, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
PDF

Article Information

vol. 39 no. 11 5927-5932

DOI

https://doi.org/10.21873/anticanres.13797

PubMed

31704817

Published By

International Institute of Anticancer Research

Print ISSN

0250-7005

Online ISSN

1791-7530

History

Received September 23, 2019
Revision received October 5, 2019
Accepted October 8, 2019
Published online November 8, 2019.

Author Information

SUSUMU NAKATA¹ ⇑,
MITSUGU FUJITA² and
HAYAO NAKANISHI³

¹Department of Clinical Oncology, Kyoto Pharmaceutical University, Kyoto, Japan
²Department of Microbiology, Faculty of Medicine, Kindai University, Osaka, Japan
³Department of Gastroenterological Surgery, Graduate School of Medicine, Nagoya University, Nagoya, Japan

Correspondence to: Susumu Nakata, MD, Ph.D., Department of Clinical Oncology, Kyoto Pharmaceutical University, Misasagi-Nakauchicho 5, Yamashina-ku, Kyoto 607-8414, Japan. Tel: +81 (0)755954719, e-mail: snakata{at}mb.kyoto-phu.ac.jp

View Full Text

Statistics from Altmetric.com

Cited By...

8 Citations
Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

hsa_circ_0000520 influences herceptin resistance in gastric cancer cells through PI3K‐Akt signaling pathway

Xukun Lv, Peizhe Li, Jinkai Wang, Hengling Gao, Yingrui Hei, Jianxian Zhang, Shuliang Li

Journal of Clinical Laboratory Analysis 2020 34 10
Insights into the structure and drug design of benzimidazole derivatives targeting the epidermal growth factor receptor (EGFR)

Mar’iyah Najihah Abdullah, Yousaf Ali, Shafida Abd Hamid

Chemical Biology & Drug Design 2022 100 6
Therapeutic Mechanism of Lapatinib Combined with Sulforaphane on Gastric Cancer

Huixing Yi, Zheming Li, Xiaoxi Liu, Shijie Dai, Shouye Li, Ho Lin

Evidence-Based Complementary and Alternative Medicine 2021 2021
Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer

Yohei Harada, Akemi Sato, Hideaki Nakamura, Keita Kai, Sho Kitamura, Tomomi Nakamura, Yuki Kurihara, Sadakatsu Ikeda, Eisaburo Sueoka, Shinya Kimura, Naoko Sueoka-Aragane

BMC Cancer 2023 23 1
Hyperpolarized [1-13C]Pyruvate Magnetic Resonance Spectroscopic Imaging for Evaluation of Early Response to Tyrosine Kinase Inhibition Therapy in Gastric Cancer

Shadi A. Esfahani, Cody Callahan, Nicholas J. Rotile, Pedram Heidari, Umar Mahmood, Peter D. Caravan, Aaron K. Grant, Yi-Fen Yen

Molecular Imaging and Biology 2022 24 5
Molecularly targeted therapy for advanced gastrointestinal noncolorectal cancer treatment: how to choose? Past, present, future

Olga Nigro, Claudio Chini, Ilaria Proserpio

Anti-Cancer Drugs 2021 32 6
HER3 PET Imaging Predicts Response to Pan Receptor Tyrosine Kinase Inhibition Therapy in Gastric Cancer

Shadi A. Esfahani, Carolina de Aguiar Ferreira, Nicholas J. Rotile, Bahar Ataeinia, Shriya Krishna, Onofrio A. Catalano, Peter Caravan, Yi-Fen Yen, Pedram Heidari, Umar Mahmood

Molecular Imaging and Biology 2023 25 2
IKZF3 amplification predicts worse prognosis especially in intestinal-type gastric cancer

Zhaomeng Cui, Huaiyu Liang, Rongkui Luo, Wen Huang, Wei Yuan, Lei Zhang, Lijuan Luan, Jieakesu Su, Jie Huang, Chen Xu, Yingyong Hou

Journal of Cancer Research and Clinical Oncology 2024 150 7

PreviousNext

In this issue

Anticancer Research

Vol. 39, Issue 11

November 2019

Table of Contents
Table of Contents (PDF)
Index by author
Back Matter (PDF)
Ed Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Efficacy of Afatinib and Lapatinib Against HER2 Gene-amplified Trastuzumab-sensitive and -resistant Human Gastric Cancer Cells

Message Subject (Your Name) has sent you a message from Anticancer Research

Message Body (Your Name) thought you would like to see the Anticancer Research web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Math question * 11 + 7 =

Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Citation Tools

Efficacy of Afatinib and Lapatinib Against HER2 Gene-amplified Trastuzumab-sensitive and -resistant Human Gastric Cancer Cells

SUSUMU NAKATA, MITSUGU FUJITA, HAYAO NAKANISHI

Anticancer Research Nov 2019, 39 (11) 5927-5932; DOI: 10.21873/anticanres.13797

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Reprints and Permissions

Efficacy of Afatinib and Lapatinib Against HER2 Gene-amplified Trastuzumab-sensitive and -resistant Human Gastric Cancer Cells

SUSUMU NAKATA, MITSUGU FUJITA, HAYAO NAKANISHI

Anticancer Research Nov 2019, 39 (11) 5927-5932; DOI: 10.21873/anticanres.13797

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
PDF

No related articles found.

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Keywords

Gastric cancer
afatinib
tyrosine kinase inhibitor
HER2
trastuzumab resistance

Main menu

User menu

Search

Efficacy of Afatinib and Lapatinib Against HER2 Gene-amplified Trastuzumab-sensitive and -resistant Human Gastric Cancer Cells

Article Information

Author Information

Statistics from Altmetric.com

Cited By...

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords